1. Home
  2. XBIO

as of 12-26-2025 4:00pm EST

$2.08
$0.10
-4.59%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

Founded: N/A Country:
United States
United States
Employees: N/A City: FRAMINGHAM
Market Cap: 5.9M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 35.9K
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.05 EPS Growth: N/A
52 Week Low/High: $1.90 - $13.93 Next Earning Date: 11-13-2025
Revenue: $2,858,935 Revenue Growth: 13.30%
Revenue Growth (this year): 1.99% Revenue Growth (next year): 20.00%

AI-Powered XBIO Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 72.41%
72.41%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: